MX2011007589A - Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20. - Google Patents
Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.Info
- Publication number
- MX2011007589A MX2011007589A MX2011007589A MX2011007589A MX2011007589A MX 2011007589 A MX2011007589 A MX 2011007589A MX 2011007589 A MX2011007589 A MX 2011007589A MX 2011007589 A MX2011007589 A MX 2011007589A MX 2011007589 A MX2011007589 A MX 2011007589A
- Authority
- MX
- Mexico
- Prior art keywords
- combination
- bendamustine
- antibody
- cancer
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002707 bendamustine Drugs 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14521009P | 2009-01-16 | 2009-01-16 | |
| PCT/US2010/021123 WO2010083365A1 (en) | 2009-01-16 | 2010-01-15 | Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011007589A true MX2011007589A (es) | 2011-08-17 |
Family
ID=42340093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011007589A MX2011007589A (es) | 2009-01-16 | 2010-01-15 | Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110274697A1 (enExample) |
| EP (1) | EP2405937A4 (enExample) |
| JP (1) | JP2012515217A (enExample) |
| KR (1) | KR20110111303A (enExample) |
| CN (1) | CN102355907A (enExample) |
| AU (1) | AU2010204666A1 (enExample) |
| BR (1) | BRPI1006829A2 (enExample) |
| CA (1) | CA2749151A1 (enExample) |
| EA (1) | EA201170940A1 (enExample) |
| IL (1) | IL213794A0 (enExample) |
| MX (1) | MX2011007589A (enExample) |
| SG (1) | SG172792A1 (enExample) |
| WO (1) | WO2010083365A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI409079B (zh) * | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法 |
| EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| CN103429606A (zh) | 2010-10-01 | 2013-12-04 | 现代治疗公司 | 设计核酸及其使用方法 |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| KR20140064873A (ko) * | 2011-08-16 | 2014-05-28 | 모르포시스 아게 | 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| FR2980110A1 (fr) * | 2011-09-20 | 2013-03-22 | Lfb Biotechnologies | Combinaison d'anticorps anti-cd20 et de bendamustine |
| KR20190099538A (ko) | 2011-10-03 | 2019-08-27 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도 |
| EP4144378A1 (en) | 2011-12-16 | 2023-03-08 | ModernaTX, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| AU2013243954A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| DK2922554T3 (en) | 2012-11-26 | 2022-05-23 | Modernatx Inc | Terminalt modificeret rna |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| BR112016007255A2 (pt) | 2013-10-03 | 2017-09-12 | Moderna Therapeutics Inc | polinucleotídeos que codificam receptor de lipoproteína de baixa densidade |
| CA3030630A1 (en) * | 2016-07-13 | 2018-01-18 | Takeda Pharmaceutical Company Limited | Combination of spleen tyrosine kinase inhibitors and other therapeutic agents |
| CN110540593B (zh) * | 2018-05-29 | 2022-05-17 | 上海药明生物技术有限公司 | 新型的抗cd3/抗cd20双特异性抗体 |
| US20210380710A1 (en) * | 2018-05-29 | 2021-12-09 | WuXi Biologics Ireland Limited | A novel anti-cd3/anti-cd20 bispecific antibody |
| EP3866783A4 (en) | 2018-10-16 | 2022-08-03 | US Nano Food & Drug Inc | INTRATUMOR INJECTION FORMULATION |
| KR20220167271A (ko) | 2020-04-13 | 2022-12-20 | 유에스 나노 푸드 앤 드럭 인코포레이티드 | 염기성 화학요법 종양내 주사 제형 |
| US20230279138A1 (en) | 2020-07-27 | 2023-09-07 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Novel bispecific anti-cd3/cd20 polypeptide complex formulation |
| GB202218493D0 (en) * | 2022-12-08 | 2023-01-25 | Oncopeptides Ab | Novel therapeutic combinations |
| WO2024179545A1 (zh) * | 2023-03-01 | 2024-09-06 | 上海津曼特生物科技有限公司 | 包含cd20/cd47阻断双功能融合蛋白的联合用药物及其用途 |
| WO2024263804A2 (en) * | 2023-06-20 | 2024-12-26 | Burzynski Stanislaw R | Compositions comprising antineoplastons and methods of treating kidney cancer |
| WO2024263801A2 (en) * | 2023-06-20 | 2024-12-26 | Burzynski Stanislaw R | Compositions comprising antineoplastons and methods of treating ovarian cancer |
| WO2024263798A1 (en) * | 2023-06-20 | 2024-12-26 | Burzynski Stanislaw R | Compositions comprising antineoplastons and methods of treating prostate cancer |
| WO2024263813A2 (en) * | 2023-06-21 | 2024-12-26 | Burzynski Stanislaw R | Compositions comprising antineoplastons and methods of treating colorectal cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2744275T3 (es) * | 2002-10-17 | 2020-02-24 | Genmab As | Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple |
| WO2005044307A2 (en) * | 2003-11-04 | 2005-05-19 | Chiron Corporation | Methods of therapy for b cell-related cancers |
| US8828392B2 (en) * | 2005-11-10 | 2014-09-09 | Topotarget Uk Limited | Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent |
| US9382327B2 (en) * | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
| US8802089B2 (en) * | 2008-01-03 | 2014-08-12 | Genmab A/S | Monoclonal antibodies against CD32B |
-
2010
- 2010-01-15 JP JP2011546347A patent/JP2012515217A/ja active Pending
- 2010-01-15 CN CN2010800123232A patent/CN102355907A/zh active Pending
- 2010-01-15 KR KR1020117018826A patent/KR20110111303A/ko not_active Withdrawn
- 2010-01-15 US US13/144,335 patent/US20110274697A1/en not_active Abandoned
- 2010-01-15 EP EP10732123A patent/EP2405937A4/en not_active Withdrawn
- 2010-01-15 CA CA2749151A patent/CA2749151A1/en not_active Abandoned
- 2010-01-15 AU AU2010204666A patent/AU2010204666A1/en not_active Abandoned
- 2010-01-15 WO PCT/US2010/021123 patent/WO2010083365A1/en not_active Ceased
- 2010-01-15 EA EA201170940A patent/EA201170940A1/ru unknown
- 2010-01-15 BR BRPI1006829A patent/BRPI1006829A2/pt not_active IP Right Cessation
- 2010-01-15 MX MX2011007589A patent/MX2011007589A/es not_active Application Discontinuation
- 2010-01-15 SG SG2011047107A patent/SG172792A1/en unknown
-
2011
- 2011-06-27 IL IL213794A patent/IL213794A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010083365A1 (en) | 2010-07-22 |
| KR20110111303A (ko) | 2011-10-10 |
| JP2012515217A (ja) | 2012-07-05 |
| EA201170940A1 (ru) | 2012-02-28 |
| CA2749151A1 (en) | 2010-07-22 |
| CN102355907A (zh) | 2012-02-15 |
| EP2405937A1 (en) | 2012-01-18 |
| IL213794A0 (en) | 2011-07-31 |
| SG172792A1 (en) | 2011-08-29 |
| BRPI1006829A2 (pt) | 2016-10-25 |
| EP2405937A4 (en) | 2012-06-20 |
| US20110274697A1 (en) | 2011-11-10 |
| AU2010204666A1 (en) | 2011-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011007589A (es) | Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20. | |
| MX2013012253A (es) | Conjugados novedosos de aglutinante-farmaco (adc) y su uso. | |
| NZ720736A (en) | Antibody drug conjugates (adcs) with kinesin spindel protein (ksp) | |
| NZ719520A (en) | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway | |
| PH12015500940A1 (en) | Bruton`s tyrosine kinase inhibitors | |
| NZ602953A (en) | Phytocannabinoids in the treatment of cancer | |
| PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
| UA112288C2 (uk) | Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими | |
| GB201111485D0 (en) | Drug composition and its use in therapy | |
| MX2011011596A (es) | Perifosina y capecitabina como un tratamiento combinado para cancer. | |
| MY173215A (en) | Acetylcysteine compositions and methods of use thereof | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| MX2020014208A (es) | Agentes terapeuticos para administracion subcutanea optimizados. | |
| PH12013501163A1 (en) | Compositions comprising a p13k inhibitor and a mek inhibitor and their use for treating cancer | |
| WO2013096335A8 (en) | ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT | |
| UA105940C2 (uk) | Лікарська комбінація з теоброміном та опіатом і її використання в лікуванні кашлю | |
| PH12012501203A1 (en) | Combination of theobromine with a decongestant and its use for the treatment of cough | |
| CR20110687A (es) | Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cancer | |
| MX2010009697A (es) | Tratamientos anticancerigenos mejorados. | |
| TN2014000418A1 (en) | Methods for treating cancer using pi3k inhibitor and mek inhibitor | |
| TN2012000256A1 (en) | Therapeutic use of protein-polymer conjugates | |
| UA82250U (ru) | Способ лечения больных с неалкогольной жировой болезнью печени | |
| UA38340U (ru) | Способ лечения женщин с патологическим прелиминарным периодом | |
| UA69269U (ru) | Способ лечения дисбактериоза у больных герпетическим стоматитом | |
| UA29192U (ru) | Адcорбирующий препарат комбинированного лечебного действия |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |